Cellectar Biosciences, Inc. — FY 2014 Form 10-K
Reporting period: Year ended December 31, 2014; filed March 24, 2015. This is an annual report, not a standalone fourth-quarter filing. Cellectar is a clinical-stage biopharmaceutical company developing cancer imaging and treatment candidates using its phospholipid ether (PLE) targeting platform. It reported no product revenue.
Financial results and liquidity
| Metric | 2014 | 2013 |
|---|---|---|
| Revenue | No product revenue | No product revenue |
| Research and development | $5.96 million | $6.86 million |
| General and administrative | $3.70 million | $4.44 million |
| Total costs and expenses | $9.89 million | $12.40 million |
| Operating loss | $9.89 million | $12.40 million |
| Net loss | $8.11 million | $10.78 million |
| Basic and diluted loss per share | $1.77 | $3.86 |
| Cash used in operating activities | $8.84 million | $9.15 million |
| Cash and cash equivalents at year-end | $9.42 million | $2.42 million |
Gross margin is not meaningful because the company had no product sales. Net loss narrowed about 25%, reflecting lower operating expenses; the improvement also included a $2.23 million noncash gain from revaluing derivative warrants. R&D expense fell 13% and G&A expense fell 17%, primarily following the 2013 restructuring. Restructuring costs were $0.22 million, down from $1.10 million.
At year-end, working capital was $7.51 million, total assets were $13.42 million, total liabilities were $2.67 million and stockholders’ equity was $10.75 million. Notes payable totaled $450,000, with $13,306 of capital lease obligations; the balance sheet also included a $1.13 million derivative liability. Restricted cash was $55,000. The company raised $13.48 million gross in an August public offering and exchanged $4.0 million of February convertible debentures and accrued interest for shares and warrants. Financing activities provided $15.87 million net cash during 2014.
Business developments and comparison with prior year
- I-124-CLR1404: PET imaging candidate in investigator-sponsored Phase 1/2 studies across solid tumors; a company-sponsored Phase 2 glioblastoma imaging study began enrolling in March 2014. FDA orphan designation for diagnostic management of glioma was granted in April 2014.
- I-131-CLR1404: The Phase 1b dose-escalation trial in advanced solid tumors completed enrollment in November 2013, with results presented in 2014. FDA accepted the multiple-myeloma IND in September 2014 and granted orphan drug designation in December 2014.
- CLR1502: Preclinical optical imaging candidate; its IND was filed in February 2015, after the fiscal year-end.
- The company completed a 1-for-20 reverse stock split in June 2014 and moved its listing from OTCQX to the NASDAQ Capital Market in August. Common shares outstanding increased from 2.87 million to 7.56 million during 2014; share and per-share data reflect the reverse split.
Outlook, risks and unusual items
Management estimated that year-end cash would fund budgeted operations through September 2015. It expects continuing operating losses and requires additional financing beyond that point; it said it planned to pursue financing alternatives but had no assurance of obtaining funding on acceptable terms. The auditor’s report and the company’s disclosures state that recurring losses and financing needs raise substantial doubt about the company’s ability to continue as a going concern. The financial statements contain no adjustments for the outcome of that uncertainty.
- Management expected to enroll the first patient in the I-131-CLR1404 multiple-myeloma proof-of-concept trial in the first quarter of 2015 and contemplated completing the I-124-CLR1404 glioblastoma Phase 2 trial during 2015, subject to funding.
- Key risks include clinical failure or safety issues, regulatory delays, dependence on external financing, dilution, manufacturing and clinical-trial execution, and lack of commercial partners or market acceptance. Most warrants contain potential dilution; 6.60 million warrants were outstanding at year-end compared with 7.56 million common shares.
- Warrant revaluation is a significant noncash earnings item and depends in part on stock-price and valuation assumptions. 2014 interest expense increased to $446,000 from $9,000, principally due to convertible-debt-related expense before the debt was exchanged.
- The Massachusetts Appeals Court affirmed the company’s favorable judgment in the ZAO BAM dispute in November 2014. Management concluded internal control over financial reporting and disclosure controls were effective at year-end; the auditor did not attest to internal control effectiveness.
Important facts for investors to verify
- Whether the company secured financing sufficient to fund operations beyond the stated September 2015 cash runway, and the resulting dilution or financing terms.
- Subsequent cash burn, liquidity, debt repayment obligations and the status of the going-concern uncertainty.
- Clinical-trial progress, safety and efficacy data, enrollment, regulatory status and actual timing for each candidate, particularly the planned multiple-myeloma and glioblastoma studies.
- Outstanding and potentially issuable shares from warrants, options and other equity awards, including any changes to derivative-warrant terms or valuation.
- Whether manufacturing capacity, third-party arrangements, intellectual-property rights and orphan designations support the proposed development plans.